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In about a quarter of patients with schizophrenia who
adhere to treatment, the illness proves refractory to
standard treatment protocols.1,2 Up to 50% of patients do
not respond to clozapine, and there is a lack of novel
pharmacological treatments.3,4 Various national and inter-
national treatment-refractory psychosis guidelines exist:1,5-7
most promote a pragmatic approach to prescribing and
patient care. Clinical practice, for various reasons, often
deviates from guideline recommendations, and one recent
large study8 demonstrated an average of ﬁve different
antipsychotics and a mean delay of 4 years before clozapine
is commenced in routine clinical practice.
The National Institute for Health and Care Excellence
(NICE) advocates the use of tertiary services for treatment-
refractory illness. The Department of Health has set out
guidelines for specialised services in mental health9 which
acknowledge that ‘centres of expertise [which] concentrate
skills and experience’ are necessary, and offer general
treatment-refractory and speciﬁc refractory psychosis
criteria (Box 1). However, there is a lack of outcome data
from specialist tertiary service in schizophrenia, despite the
prevalence and burden of treatment resistance. This work
aimed to explore outcome measures of one such in-patient
service: assessing clinical change from admission to
discharge, with preliminary modelling of potential cost-
effectiveness. Although data on tertiary care in psychosis
are limited, we predicted that admission to the National
Psychosis Unit would result in multidomain clinical
improvements and this would prove cost-effective.
Method
The clinical notes of patients admitted to the National
Psychosis Unit between 2001 and 2007 were collated for
retrospective analysis using the OPCRIT system. This is a
reliable and well-validated tool utilising an electronic
checklist of psychopathological symptoms that are scored,
with algorithms for clinical diagnosis.10 The notes on
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Aims and method In up to a quarter of patients, schizophrenia is resistant to
standard treatments. We undertook a naturalistic study of 153 patients treated in the
tertiary referral in-patient unit of the National Psychosis Service based at the
Maudsley Hospital in London. A retrospective analysis of symptoms on admission and
discharge was undertaken using the OPCRIT tool, along with preliminary economic
modelling of potential costs related to changes in accommodation.
Results In-patient treatment demonstrated statistically signiﬁcant improvements in
all symptom categories in patients already identiﬁed as having schizophrenia
refractory to standard secondary care. The preliminary cost analysis showed net
savings to referring authorities due to changes from pre- to post-discharge
accommodation.
Clinical implications Despite the enormous clinical, personal and societal burden of
refractory psychotic illnesses, there is insufﬁcient information on the outcomes of
specialised tertiary-level care. Our pilot data support its utility in all domains
measured.
Declaration of interest S.N.S., D.K.T., M.-J.M.F., G.D., J.O., A.-M.P., K.S., F.G. and
S.S.S. work, or have worked, on the National Psychosis Unit where the study was
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admission to, and discharge from, the National Psychosis
Unit were assessed to give comparative OPCRIT scores for
each time point. Of 182 sequential notes, 153 had sufﬁciently
detailed clinical information at the time of admission and of
discharge for such assessment and accurate completion of
OPCRIT scores at the two time points to be made. All
patients, 86 male and 67 female, met ICD-10 criteria for a
primary diagnosis of schizophrenia, with 36 having a co-
existent Axis II diagnosis: 36 had a lifetime history of
alcohol dependence or harmful use (24 at the point of
admission); 49 a lifetime history of cannabis dependence or
harmful use (37 at the point of admission); and 31 a lifetime
history of harmful use or dependency on other substances
(23 on admission). The mean age on admission was 33 years
(s.d. = 10.9), and mean length of stay on the unit was 254
days (s.d. = 169). Thirty patients had their ﬁrst psychotic
episode before the age of 16; in 53 patients it occurred
between 17 and 20 years old; in 29, between 21 and 25 years;
in 20, between 26 and 35; and 12 had their ﬁrst episode after
the age of 35. At the time of admission, 21 patients were
on clozapine monotherapy and 55 patients were taking
clozapine with a second antipsychotic.
To evaluate whether there was a signiﬁcant difference
between admission and discharge scores, paired-samples
t-tests were conducted on the scores for appearance and
behaviour, speech and form of thought, affect and associated
features, abnormal beliefs and ideas, abnormal perceptions,
and total clinical score. Signiﬁcance was ascribed according
to a false-discovery rate (FDR) corrected P-threshold of 0.05
having corrected for the number of variables tested.
Sufﬁcient data were available to allow a preliminary
analysis of the costs of the pre-admission and post-
discharge social care for 96 of the patients admitted. Costs
were based on the patient’s clinical setting immediately
prior to admission v. immediately post-discharge, which
were categorised as home, residential placement, residential
rehabilitation unit, hospital in-patient unit and psychiatric
intensive care unit. Costs associated with each setting were
estimated by extrapolating baseline data from a previous
local study of people with schizophrenia in equivalent
settings.11 That study obtained costing estimate data from
various (UK) sources and involved: social security beneﬁt
rates from the UK Department for Work and Pensions;
police contact costs; specialist education services costs
based on data from the Chartered Institute of Public
Finance and Accountancy; medication costs from data in
the Joint Formulary Committee; and health and social care
service costs based on national estimates - for references see
Patel et al.11 Costs in this current study were standardised to
one-year periods and updated to 2011/2012 prices.
Results
Clinical outcomes from admission to discharge
Admission and discharge OPCRIT scores were obtained for all
153 case notes. There was a statistically signiﬁcant decrease in
symptom scores in all domains between admission and
discharge (Fig. 1: times 1 and 2 respectively). Signiﬁcant
improvement was seen in: appearance and behaviour
(t(152) = 7.70, P-FDR-corrected=9.8610-12); speech and form
of thought (t(152) = 7.20, P-FDR-corrected= 1.9610-10); affect
and associated features (t(152) = 11.53, P-FDR-corrected=
1.0610-21); abnormal beliefs and ideas (t(152) = 11.67, P-FDR-
corrected = 4.4610-22); abnormal perceptions (t(152) = 8.63,
P-FDR-corrected = 4.7610-14); and global clinical score
(t(152) = 12.72, P-FDR-corrected = 5.6610-25). A breakdown
of OPCRIT scores by pre- and post-admission residency is
shown in Box 1. Of note, at the time of discharge, 16 of those
admitted on clozapine had had their dose increased, and an
additional 63 patients had been commenced on this drug.
Cost analysis
At discharge, the majority of patients moved to the same
(44.8%) or lower- (also 44.8%) intensity setting as
compared with their pre-admission setting (Table 1).
There was an estimated average saving of £20 929 per
person per year between pre-admission and post-discharge
accommodation costs. The greatest savings were for those
who came from the highest-intensity setting, at an
estimated average of £41 358 per person, because many of
these moved to a lower-intensity setting post-discharge.
Those who moved to a lower-intensity setting (n = 43) had a
higher National Psychosis Unit admission cost (£143 493 v.
£98 020; P-value from t-test 0.009) than those who returned
to the same or a higher-intensity setting. They also had a
greater OPRIT Mental State Examination score improvement
(19 v. 9 points; P = 0.002).
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Box 1 Proposed criteria for complex and/or refractory
disorder services generally, and psychosis services
speciﬁcally
Generic complex/refractory criteria
. Diagnostic uncertainty hampering treatment
. Persistently high symptom burden
. Signiﬁcant impact on functioning
. Persisting (42 years) pattern of incapacity despite
appropriate treatment
. Multiple comorbidities increasing likelihood of chronicity
. Need for specialised treatments (e.g. transcranial magnetic
stimulation)
. In-patient stay 46-12 months
Speciﬁc to a psychosis centre
. Failure to respond adequately (or tolerate) two
antipsychotics (at least one atypical)
. Attempted adequate trial of clozapine, usually for a
minimum of 6-9 months
. Appropriate psychological therapies such as cognitive-
behavioural therapy and family interventions should have
been attempted
Abridged and amended from Department of Health guidelines.9
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Discussion
Research in refractory psychosis has generally focused on
speciﬁc individual pharmacological, psychological or socio-
logical interventions, and far less work has explored
specialist tertiary units. Undoubtedly such atypical sites
have many confounders, including staff make-up and skills,
and a cohort of patients whose psychosis is treatment-
refractory. Nevertheless, evaluating the work of centres of
proposed excellence is clearly worthwhile. Works by Nirodi
et al,12 Ker & Anderson13 and Shepherd et al14 describe the
difﬁculties and rationale for tertiary services more broadly,
particularly for treatment-resistant depression, and some of
these arguments can be equally considered for refractory
psychosis. The nature of commissioning and costing of
services in the UK and a push towards primary care
management of common disorders mitigate against
specialist services. Furthermore, a culture of senior
clinicians feeling variously that they ‘should’ know how to
manage ‘difﬁcult’ cases, clinical insecurity or clinical
overconﬁdence might be barriers to obtaining a second
opinion. However, tertiary care can be argued to afford
three broad advantages. First, ‘general’ psychiatrists cannot
realistically remain experts in all conditions and with the
most recent research developments, nor will they necessarily
have the multidisciplinary resources to implement them.
Second, specialist services can act as an expert resource for
consultation and in training generalists, aiding clinical
development and conﬁdence. Third, the academic links
typically found in centres of excellence facilitate evaluation
andmore rapid integration of novel therapeutic developments.
Study limitations
There are a few caveats that require highlighting when
reviewing a naturalistic data-set with no control group.
Primary issues are that a full data-set was not available for
all those admitted; comparisons were only possible at two
time points in individuals; patients are admitted when
chronically unwell and failing to respond to treatment, and
may potentially be unlikely to be offered medically
recommended discharge until some improvement is
shown; adherence to medication may be better in a closely
monitored in-patient unit. Nevertheless, there was evidence
for a statistically signiﬁcant improvement, across all clinical
domains, in a cohort of patients with psychosis deemed
unresponsive to standardised secondary care. Although the
OPCRIT is considered a reliable and well-validated tool, its
design was primarily for extracting diagnostic information
from case notes. Its use in retrospective data collection and
as a mechanism for scaling symptom severity is open to
challenge15 and one cannot exclude the inadvertent biases
introduced during the rating process. Two of the authors
(S.N.S. and G.D.), both psychiatrists, collected the OPCRIT
data: they undertook interrater reliability training, and a
test-retest on a random sample of ten sets of notes showed
good reliability. The costings model is inevitably somewhat
crude, but the factors utilised were those that were
identiﬁed from earlier cost-effectiveness studies and
consistently noted in the patient records. Nevertheless,
future work might undertake a more rigorous exploration
of pre- and post-treatment costs as well as longer-term
follow-up of clinical and ﬁnancial outcomes over several
years. The patient/demographic variables, illness variables
(such as duration of illness, number and length of episodes),
and clinical input variables (duration of admission, number
and nature of treatments trialled) were not explored as data
variables. Inevitably with the well-established issue of
responder bias, the ﬁndings of any survey with low total
numbers must be interpreted judiciously.
Challenges to tertiary services
There are several logistical challenges in provision of
specialist services, particularly where these are geographically
distant from the patient’s home, making the necessary
communication with carers and locality more challenging.
There are some approaches which can mitigate these to
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Fig 1 Mean OPCRIT scores from admission to discharge, with 95%
conﬁdence interval error bars.
Table 1 Patient admission and discharge residencies (data available for 96 patients), and mean and standard deviation
(s.d.) OPCRIT scores
Accommodation type Number at admission
OPCRIT score at
admission (s.d.) Number at discharge
OPCRIT score at
discharge (s.d.)
Home 25 24.6 (14) 28 11.3 (10)
Residential placement 2 18.0 (1) 26 11.4 (11)
Residential rehabilitation unit 13 28.5 (11) 21 17.5 (12)
In-patient/PICU 56 33.9 (15) 21 31.6 (21)
Overall 96 30.4 (15) 96 17.2 (16)
PICU, psychiatric intensive care unit.
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some degree; for example, the National Psychosis Unit holds
monthly carers’ groups with an aim of providing access to
support and information and to discuss their lived
experiences. In this context, the care programme approach
provides an essential framework for regular communication
between the locality teams, carers and the specialist centre
and, in our experience, this forum is viewed very positively
by all participants. Finally, the National Psychosis Unit is
unusual in being integrated with the Psychosis Clinical
Academic Group at the Institute of Psychiatry, King’s
College London, enabling very close links with active
researchers and access to novel treatments.16-18 State-of-
the-art investigations19-21 and therapeutic monitoring are
easily available, as are the necessary liaison with specialised
pharmacy, haematology and cardiology. The recovery-based
focus is also facilitated by access to a full range of
occupational therapeutic and highly specialised psychological
therapies for psychosis. Our initial ﬁndings support the
effectiveness of admission to a specialist in-patient service,
but longer-term prospective data are required, particularly
looking at the speciﬁc patient and clinical input factors that
might affect outcomes.22-24
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